Si-Bone06.05.20
Si-Bone Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, has announced that Aetna has established a positive coverage policy for minimally invasive SI joint fusion.
The new policy covers minimally invasive arthrodesis of the sacroiliac joint (e.g., iFuse) for sacroiliac joint syndrome and sacroiliac joint pain. This decision was based upon published clinical evidence demonstrating the safety and effectiveness of the iFuse Implant System, including recently published 5-year results from a long-term prospective study called LOIS (Long Term Outcomes from INSITE and SIFI).
“As a result of this positive coverage decision, Aetna’s 22 million medical plan members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, president, CEO and chairman at SI-BONE. “Aetna’s decision to cover MIS SI joint fusion with iFuse is a significant milestone and further expands access and adoption of this important treatment option for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”
Aetna is the third largest commercial health plan in the United States with over 22 million members. The new policy becomes effective May 28, 2020.
The new policy covers minimally invasive arthrodesis of the sacroiliac joint (e.g., iFuse) for sacroiliac joint syndrome and sacroiliac joint pain. This decision was based upon published clinical evidence demonstrating the safety and effectiveness of the iFuse Implant System, including recently published 5-year results from a long-term prospective study called LOIS (Long Term Outcomes from INSITE and SIFI).
“As a result of this positive coverage decision, Aetna’s 22 million medical plan members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, president, CEO and chairman at SI-BONE. “Aetna’s decision to cover MIS SI joint fusion with iFuse is a significant milestone and further expands access and adoption of this important treatment option for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”
Aetna is the third largest commercial health plan in the United States with over 22 million members. The new policy becomes effective May 28, 2020.